Get the Stockscreener App
3.01
3.08%
0.09
Pre-market:
3.04
0.03
+1.00%
Genelux Corp stock is traded at $3.01, with a volume of 114.17K.
It is up +3.08% in the last 24 hours and up +19.44% over the past month.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
See More
Previous Close:
$2.92
Open:
$2.94
24h Volume:
114.17K
Relative Volume:
0.63
Market Cap:
$134.97M
Revenue:
$8,000
Net Income/Loss:
$-32.15M
P/E Ratio:
-3.4758
EPS:
-0.866
Net Cash Flow:
$-26.37M
1W Performance:
+7.50%
1M Performance:
+19.44%
6M Performance:
-46.15%
1Y Performance:
+16.67%
1-Day Range:
$2.94
$3.1679
1-Week Range:
$2.78
$3.1679
52-Week Range:
$2.29
$8.535
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.01 | 130.93M | 8,000 | -32.15M | -26.37M | -0.866 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Lake Street | Buy |
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
View All
Genelux Corp Stock (GNLX) Latest News
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux president and CEO Zindrick Thomas sells $8,225 in stock By Investing.com - Investing.com Australia
Genelux CSO Yu Yong sells $1,798 of common stock - Investing.com UK
Genelux CSO Yu Yong sells $1,798 of common stock By Investing.com - Investing.com Nigeria
Genelux CTO Joseph Cappello sells $1,799 in company stock By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $804 in stock By Investing.com - Investing.com Nigeria
Genelux president and CEO Zindrick Thomas sells $8,225 in stock - Investing.com
Genelux CTO Joseph Cappello sells $1,799 in company stock - Investing.com
Genelux head of regulatory sells $804 in stock - Investing.com
Genelux (GNLX) CSO Yu Yong sells 605 shares to cover RSU tax bill - Stock Titan
Research Analysts Offer Predictions for Genelux Q2 Earnings - MarketBeat
GENELUX (GNLX) CEO Zindrick sells 2,798 shares for RSU tax obligations - Stock Titan
Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained - TipRanks
Genelux : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Ovarian cancer trial readout due in 2H26 as Genelux cash lasts to 1Q27 - Stock Titan
GENELUX Corp 1Q 2026: Revenue $0 Net loss $8.9M, EPS $(0.20) — 10-Q Summary - TradingView
Genelux (GNLX) raises $18.5M, extends cash runway into 2027 - Stock Titan
GNLX Stock Price, Quote & Chart | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView
[ARS] GENELUX Corp SEC Filing - Stock Titan
Genelux (NASDAQ: GNLX) details 2026 virtual meeting, board and auditor votes - Stock Titan
Genelux (GNLX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Olvi Vec could reshape advanced ovarian cancer treatment, Genelux claims - Traders Union
Genelux Corporation (GNLX) Stock: Technical Signals (Technical Weakness) 2026-04-20Live Trade Sharing - Newser
Genelux advances next generation oncolytic immunotherapies for cancer treatment - Traders Union
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - MarketBeat
Is Genelux Corporation (GNLX) Stock Good for Short Term | Price at $2.45, Down 7.20%Elite Trading Signals - newser.com
GNLX Stock Analysis: Genelux Corporation Holds Near 2.57 Level With Modest Daily Gain - Newser
GNLX Technical Analysis & Stock Price Forecast - Intellectia AI
Analyst Calls: Can Genelux Corporation outperform in the next rally2026 Market Outlook & AI Driven Price Predictions - baoquankhu1.vn
GNLX PE Ratio & Valuation, Is GNLX Overvalued - Intellectia AI
Genelux head of regulatory sells $1.4k in shares By Investing.com - Investing.com Australia
Yu Yong, Genelux SVP, sells $2192 in GNLX stock By Investing.com - in.investing.com
Genelux CEO Zindrick sells $8668 in shares By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $1.4k in shares - investing.com
Cappello, Genelux CTO, sells $2192 in GNLX stock By Investing.com - Investing.com South Africa
Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):